Hyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury

Dagel, Tuncay; Misirlioglu, Selim; Tanju, Serhan; AFŞAR, Barış; Selcukbiriciks, Fatih; Erus, Suat; Vatansever, Dogan; Bank, Emre; Taskiran, Cagatay; Dilege, Sukru; Mandel, Nil; Bugra, Dursun; Yalti, Tunc; Kanbay, Mehmet

Hyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury

Copy For Citation

Dagel T., Misirlioglu S., Tanju S., AFŞAR B., Selcukbiriciks F., Erus S., ...More

JOURNAL OF BUON, vol.23, no.5, pp.1528-1533, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 23 Issue: 5
Publication Date: 2018
Journal Name: JOURNAL OF BUON
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1528-1533
Süleyman Demirel University Affiliated: Yes

Abstract

Purpose: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) or hyperthermic intrapleural chemotherapy (HIC) has been established as the new treatment modality for selected patients with peritoneal and pleural malignancies. The purpose of the study was to compare the development of acute kidney injury (AKI) in patients who received intravenous cisplatin alone, HIPEC and underwent surgery.